2019-09-02 Dongsheng Zhu, Department of Urology,Tianjin Medical University Second Hospital, China (mainland)
Dear Editor,
In a recent issue of Medical Science Monitor, Hua Zhang and his workmates published an article [1] entitled “Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer”,which we read with great interest. We congratulate the authors for their efforts. In this study, the investigators use colony formation, MTT assays Flow cytometry and transwell invasion assay, finding that high KIF18A expression in prostate cancer patients predicts a poor prognosis and knockdown KIF18A inhibits prostate cell proliferation and metastasis. In addition, the results of this study is confirms the usefulness of KIF18A as an oncological prognostic indicator and a potential therapeutic target for prostate cancer.
This article provides valuable information about the KIF18A in prostate cancer. However, we have several opinions and suggestions that we would like to communicate to the investigators, at present, the most useful biomarker of prostate cancer is the level of prostate-specific antigen (PSA), and it is one of the most effective serum biomarkers available and has been used in clinical practice for serval years. I want to know, KIF18A and PSA, who is more effective, more convenient to detect, more clinical value? Can KIF18A replace the role of PSA in the diagnosis and detection of recurrence of prostate cancer?


1. Zhang H, Shen T, Zhang Z, et al: Expression of KIF18A Is Associated with Increased Tumor Stage and Cell Proliferation in Prostate Cancer. Medical science monitor : international medical journal of experimental and clinical research 2019, 25:6418-6428